Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
Clinical trial NCT03680521 · COMPLETED
Trial details
- NCT number
- NCT03680521
- Sponsor
- Mirati Therapeutics Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-10
- Primary completion
- 2020-04-27
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.